CN105582037A - Medicine composition for treating bacterial diseases of poultry - Google Patents
Medicine composition for treating bacterial diseases of poultry Download PDFInfo
- Publication number
- CN105582037A CN105582037A CN201610054946.5A CN201610054946A CN105582037A CN 105582037 A CN105582037 A CN 105582037A CN 201610054946 A CN201610054946 A CN 201610054946A CN 105582037 A CN105582037 A CN 105582037A
- Authority
- CN
- China
- Prior art keywords
- parts
- poultry
- disease
- medicine composition
- barberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 244000144977 poultry Species 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 208000035143 Bacterial infection Diseases 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 235000016068 Berberis vulgaris Nutrition 0.000 claims abstract description 20
- 229920001983 poloxamer Polymers 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960000502 poloxamer Drugs 0.000 claims abstract description 18
- 241000287828 Gallus gallus Species 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims description 32
- 241001083847 Berberis Species 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000000227 grinding Methods 0.000 claims description 16
- 206010012735 Diarrhoea Diseases 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 241001478212 Riemerella anatipestifer Species 0.000 claims description 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 241000272525 Anas platyrhynchos Species 0.000 claims description 3
- 239000003595 mist Substances 0.000 claims description 2
- 241000305071 Enterobacterales Species 0.000 claims 1
- 241000272517 Anseriformes Species 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 4
- 240000000724 Berberis vulgaris Species 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 abstract description 2
- 235000013594 poultry meat Nutrition 0.000 abstract 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- 235000001855 Portulaca oleracea Nutrition 0.000 description 11
- 241000219304 Portulacaceae Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000004062 sedimentation Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010071301 Perihepatitis Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000009361 aviculture Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- -1 shitosan Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides medicine composition for treating bacterial diseases of poultry. The medicine composition is a dry suspension prepared from raw materials in parts by weight as follows: 6.67-80.04 parts of herba portulacae, 3.33-39.96 parts of barberry roots, 8-16 parts of sorbitol and 0-4 parts of poloxamer. The invention further provides a preparation method and an application of the medicine composition. The medicine composition is prepared from the specific raw materials in specific quantity and can effectively treat colibacillosis of chickens and ducks, pullorum disease and remerella anatipestifer disease, and the cure rate reaches 92%. The medicine composition is easy to take for poultry, is efficient, low in price, safe, stable in quality, simple in process and convenient to use, store and transport and has wide market prospect, and a new medicine for treating the bacterial diseases of poultry clinically is provided.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of poultry bacterial disease and preparation method thereof and useBelong to drug world on the way.
Background technology
The poultry farming of China is very flourishing, in recent years, and along with home poultry raising scale constantly expands, fowlProducts in circulation are accelerated day by day, and poultry bacterial catches and also becomes increasingly complex, mixed infection is more and more generalTime, the variation of pathogenic microorganism is more and more serious, has brought huge to the treatment of poultry bacterial diseaseDifficulty. Up to the present, the bacteriosis that poultry is main, as chicken/E. coli isolated from ducks disease, white diarrhea andRiemerella anatipestifer diseases etc., the overwhelming majority has generation in China.
The early stage treatment to poultry bacterial disease, the main antibacterials that use both at home and abroad, as clinical conventionalPolytype antimicrobial such as aminoglycoside, polypeptide class, polyenoid class, sulfamido and TrimethoprimThing. A large amount of uses of antibacterials and unreasonable use or even misuse, abuse to aviculture and causedA series of serious consequences: it is even invalid that bacterial drug resistance increases rapidly, antibacterials curative effect declines. Chinese medicineDerive from animal, plant or mineral matter, be difficult for making pathogenic bacteria to produce drug resistance, internal metabolism is very fast, heightEffect low toxicity noresidue, both can restraining and sterilizing bacteria, can strengthen again animal body immunologic function. Application number:201310065234.X denomination of invention: the combination medicine for the treatment of piglet yellow-white dysentery discloses a kind of micro-capsuleAgent, is prepared from by the supplementary material that contains following weight proportion: the capsule heart and capsule material mass ratio are 1:(1-5);Wherein, the capsule heart is water or the extractive with organic solvent of barberry (1 part) and purslane (2 parts); Capsule materialFor gelatin, Arabic gum, alginate, shitosan, carboxymethyl cellulose salt, ethyl cellulose, firstThe combination of one or more in base cellulose, Hydroxypropyl methylcellulose. This microcapsules preparation technology is multipleAssorted and for the short poultry of esophagus, swallow very difficult, the stress reaction being caused by aphetite disorderMake poultry easily frightened and impact is grown.
Therefore, find one and be suitable for poultry and swallow, efficient, inexpensive, safety, steady quality, technique letterSingle, easy to use, to be convenient to storage and transport novel drugs, has clinical treatment poultry bacterial diseaseVery important meaning.
Summary of the invention
Technical scheme of the present invention be to provide a kind of pharmaceutical composition for the treatment of poultry bacterial disease andPreparation method and purposes.
The invention provides a kind of pharmaceutical composition for the treatment of poultry bacterial disease, it is by following weightThe dry suspensoid agent that the raw material of proportioning is prepared from:
Herba portulacae 6.67-80.04 part, barberry 3.33-39.96 part, sorbierite 8-16 part, poloxamer0-4 part.
Preferably, described pharmaceutical composition is the dry suspensoid agent being prepared from by the raw material of following weight proportioning:
Herba portulacae 66.67g part, 33.33 parts of barberries, 16 parts of sorbierites, 2 parts of poloxamers.
The method that the invention provides the described pharmaceutical composition of preparation, comprises the steps:
A, the Herba portulacae of getting recipe quantity, barberry are pulverized respectively, mix, then carry out ultramicro grinding, obtain superMicro mist;
B, the Ultramicro-powder of getting step a add sorbierite, poloxamer, decoct, and dry, and pulverize, sieve,Obtain.
Wherein, in step a, Herba portulacae, barberry are pulverized respectively as fine powder, crossed 65 mesh sieves, then use" V " type mixer mixes 1 hour; In step b, decoct 15-60 minute, dry to moistureBelow 10%, cross 100-400 mesh sieve.
Preferably, in step b, decoct 15 minutes, cross 400 mesh sieves.
The present invention also provides described pharmaceutical composition in the medicine of preparation treatment poultry bacterial diseasePurposes.
Wherein, described medicine is treatment chicken/E. coli isolated from ducks disease, white diarrhea and Riemerella anatipestifer diseaseMedicine.
Pharmaceutical composition of the present invention is prepared under specific consumption by specific supplementary material, can effectively treatChicken/E. coli isolated from ducks disease, white diarrhea and Riemerella anatipestifer disease, cure rate all reaches 92%. The present inventionPharmaceutical composition is efficient, safety, steady quality, easy to use, technique is simple, is clinical treatment poultryBacteriosis provides a kind of new medicine, has wide market prospects.
Below by detailed description of the invention, the present invention is described in further detail, but do not limit thisBright, various changes and replacement that those skilled in the art make according to the present invention, only otherwise depart from the present inventionSpirit, all should belong to the scope of claims of the present invention.
Detailed description of the invention
The preparation of embodiment 1 pharmaceutical composition of the present invention
Prescription is as follows: purslane 66.67g, barberry 33.33g, sorbierite 16g, pool Luo Samu 2g
Preparation method is as follows:
A, get Herba portulacae, barberry and pulverize respectively as fine powder, cross 65 mesh sieves, then use " V " type to mixMachine mixes 1 hour, after taking-up, is crushed to completely by No. 9 sieves (200 orders, particle diameters with micronizerM), by 800 orders, (the 15 μ m) powder of screen cloth should be greater than 50% of total amount to 75 μ;
B, the Ultramicro-powder of getting step a add sorbierite, pool Luo Samu, decoct 15 minutes, dry to waterPoint content is below 10%, and (38 μ m) and get final product to cross 400 mesh sieves.
The preparation of embodiment 2 pharmaceutical compositions of the present invention
Prescription is as follows: purslane 6.67g, barberry 3.33g, sorbierite 8g
Preparation method is as follows:
A, get Herba portulacae, barberry and pulverize respectively as fine powder, cross 65 mesh sieves, then use " V " type to mixMachine mixes 1 hour, after taking-up, is crushed to completely by No. 9 sieves (200 orders, particle diameters with micronizerM), by 800 orders, (the 15 μ m) powder of screen cloth should be greater than 50% of total amount to 75 μ;
B, the Ultramicro-powder of getting step a add sorbierite, decoct 30 minutes, dry to moisture 10%Below, (38 μ m) and get final product to cross 100 mesh sieves.
The preparation of embodiment 3 pharmaceutical compositions of the present invention
Prescription is as follows: purslane 80.04g, barberry 39.96g, sorbierite 16g, pool Luo Samu 4g
Preparation method is as follows:
A, get Herba portulacae, barberry and pulverize respectively as fine powder, cross 65 mesh sieves, then use " V " type to mixMachine mixes 1 hour, after taking-up, is crushed to completely by No. 9 sieves (200 orders, particle diameters with micronizerM), by 800 orders, (the 15 μ m) powder of screen cloth should be greater than 50% of total amount to 75 μ;
B, the Ultramicro-powder of getting step a add sorbierite, pool Luo Samu, decoct 60 minutes, dry to waterPoint content is below 10%, and (38 μ m) and get final product to cross 200 mesh sieves.
Prove beneficial effect of the present invention by specific experiment below.
Experimental example 1
1 material
1.1 medicinal material
Purslane, Sichuan, the place of production, purchased from Sichuan Qianfang Traditional Chinese Medicine Tablet Co., Ltd., lot number 20110301;Radix berberidis, Sichuan, the place of production, purchased from Sichuan Qianfang Traditional Chinese Medicine Tablet Co., Ltd., lot number 20101203.
1.2 equipment
FS-130 type pulverizer, Chinese light sky, Shijiazhuang closes packaging pharmaceutical machine Co., Ltd, and LWF6-A is superAtomizer, Jinan Long Wei pharmaceutical equipment Co., Ltd. LS-330 shaking screen, Chongqing work drying equipment is limitedCompany; VH-14V type mixer, Jishou Zhong Cheng pharmaceutical machine factory.
1.3 experimental animal
Chicken colibacillosis, E. coli isolated from ducks disease, white diarrhea (chick) and duck oromeningitis patient and his family fowl each 150Only, provide by prosperous plant.
2 are dry mixed the preparation of outstanding powder
The preparation of 2.1 Ultramicro-powders
First use Ordinary pulverization machine by 1 part of 2 parts of purslanes and barberry, pulverize respectively as fine powder is (by 5Number sieve, 65 orders, particle diameter 180 μ m). Then by mixed by " V " type to purslane powder and barberry powderThe machine that closes mixes 1 hour, after taking-up, is crushed to completely by No. 9 sieves (200 orders, grains with micronizerM), by 800 orders, (the 15 μ m) powder of screen cloth should be greater than 50% of total amount, i.e. Chinese medicine to footpath 75 μUltramicro-powder, both destroyed most plant cell wall, do not destroy again the molecular structure of Chinese medicine, protectDemonstrate,prove the Fast Stripping of property of medicine composition.
2.2 are dry mixed the preparation of outstanding powder
2.2.1 preparation condition primary election
According to administration time with medication easily principle this preparation is decided to be and is dry mixed outstanding powder, it is at water soIn the suspending stabilized time should more than 12 hours, can reach and produce actual requirement. Tentatively draft this productPreparation method, in sample, suspending composition is containing sorbierite 8g, poloxamer 2g, when decoction in every 10gBetween be 30 minutes, dry to moisture below 10%, grinding particle size be all by 200 mesh sieves (grainFootpath 75 μ m ± 4.1 μ m), add water and stir in the ratio of 1:10, observe sedimentation situation, the results are shown inTable 1.
Table 1 is dry mixed the preparation of outstanding powder
Result shows: sample 4 suspend without the time of sedimentation the longest, show the optimal stability of medicine, because ofThis preferred preparation method is: Chinese herbal ultra-fine powder is mixed with suspending composition, by decocting, dry, pulverizingStep is prepared dry suspensoid agent of the present invention.
2.2.2 be dry mixed the preparation technology's of outstanding powder optimization
The screening of sorbierite, poloxamer consumption, decocting time and grinding particle size, takes off and states consumption proportionSorbierite, poloxamer and Ultramicro-powder mix in the ratio of 1:10 after, prepare under the following conditions various kindsProduct, observe sedimentation situation.
Laboratory sample:
Sample 1: sorbierite 4g, poloxamer 1g, decocting time 15min, grinding particle size 100 orders
Sample 2: sorbierite 4g, poloxamer 2g, decocting time 30min, grinding particle size 200 orders
Sample 3: sorbierite 4g, poloxamer 4g, decocting time 60min, grinding particle size 400 orders
Sample 4: sorbierite 8g, poloxamer 1g, decocting time 30min, grinding particle size 400 orders
Sample 5: sorbierite 8g, poloxamer 2g, decocting time 60min, grinding particle size 100 orders
Sample 6: sorbierite 8g, poloxamer 4g, decocting time 15min, grinding particle size 200 orders
Sample 7: sorbierite 16g, poloxamer 1g, decocting time 60min, grinding particle size 200 orders
Sample 8: sorbierite 16g, poloxamer 2g, decocting time 15min, grinding particle size 400 orders
Sample 9: sorbierite 16g, poloxamer 4g, decocting time 30min, grinding particle size 100 orders
Sample 10: sorbierite 16g, poloxamer 0g, decocting time 30min, grinding particle size 400 ordersExperimental result:
Table 2 result of the test statistical form
Description of symbols: by alphabetical sequencing, from big to small mark. Mark same letter differences between samples not remarkable, such as 14a and 13a poorDifferent not remarkable, 14 is all remarkable with other data difference, so other samples do not mark a, the like.
Result shows: sample 8 and sample 10 suspend without time of sedimentation all more than 12 hours, can reachTo producing actual requirement (with other sample comparisons, significant difference p < 0.1), wherein sample 8 suspension nothingsThe time of sedimentation is the longest, optimal stability, and therefore, optimizing technology parameters is: 100g purslane and threeIn the mixing Ultramicro-powder of pin, add sorbierite 16g and poloxamer 2g, decoct 15 minutes, pulverize grainDegree is that (38 μ m) for 400 orders.
2.2.3 the screening of Ultramicro-powder addition
Respectively by Ultramicro-powder 10g, 40g, 80g, 100g, 120g, 160g, add sorbierite 16g andPoloxamer 2g, decocts 15 minutes, and grinding particle size is that 400 orders (38 μ m), are prepared different contentDry suspensoid agent, observes sedimentation situation, in table 3.
Table 3 Ultramicro-powder addition result statistical form
Result shows, is adding sorbierite 16g, poloxamer 2g, decocts 15 minutes, and grinding particle size isUnder 400 object conditions, the addition 10g-120g of Ultramicro-powder all can prepare qualified dry suspensoid agent, considersEconomy and practical application, preferably Ultramicro-powder addition is 100g.
The clinical testing of experimental example 2 dry suspensoid agents of the present invention
" Chinese veterinary pharmacopoeia " regulation purslane is 1.5-6g for the dosage of poultry, and the consumption of barberry is1-3g, with dry suspensoid agent 4g of the present invention (approximately containing purslane 2.296g, barberry 1.148, sorbierite 0.552)As the maximum dose level of clinical application, i.e. barberry and the purslane consumption that all conforms with the regulations, using 4 times asIt is 1g that multiple proportions arranges middle dosage, and low dosage is 0.25g. Usage, for after this product is added to suitable quantity of water and mixes, addsEnter in water fountain, before dispensing, cut off the water supply half a day, administration every day 1 time, is used in conjunction 3 days. Control group hydrochloric acidCiprofloxacin soluble powder, dosage is 50mg/L water, administration every day 2 times, is used in conjunction 3 days.
1 white diarrhea
This disease is a kind of extremely common infectious disease, is caused by white diarrhea Salmonella, and its excreta isImportant communication media, also can pass through egg vertical transmission simultaneously. Chick shows as and does not eat feed, is afraid of cold,Health is rolled up, and wing is sagging, spirit depressed or lethargic sleep, arrange white thickness or yellowish, light green is just rare,The excrement piece that anus is hardened sometimes seals, and expiratory dyspnea, the results are shown in Table 4.
The therapeutic test of table 4 white diarrhea
Result shows: the cure rate of high, the middle dosage group of test group is more than 90%, shows that the present invention is dryThe effect of supensoid agent treatment white diarrhea is remarkable.
2 avian colibacillosis
Chicken colibacillosis is caused by enteropathogenic E．Coli. Show as One's spirits are drooping depressed, search for foodReduce or do not eat, peel off slow-witted vertical or squat motionless, hat whisker is livid purple look, an eye iris is canescence, eyesightGo down or loose random, the anus of blind, feather around feather be stained with ight soil, green or yellow-white loose stool, squat,Can not stand, be reluctant that moving or limping, arthrocele, hepatomegaly, intestinal mucosa hemorrhage and ulcer, pericardium send outScorching, abdominal cavity is long-pending ascites, the results are shown in Table 5,6.
The therapeutic test of table 5 chicken colibacillosis
The therapeutic test of table 6 E. coli isolated from ducks disease
Result demonstration, the cure rate of chicken and high, the middle dosage group of duck test group is more than 90%, shows thisThe effect of invention dry suspensoid agent treatment chicken/E. coli isolated from ducks disease is remarkable.
3 Riemerella anatipestifer diseases
This disease is more common in the duckling in age in 1-8 week, is acute or chronic septicemia, faces to examine main manifestations and beEye and nasal discharge increase, breathe, cough, diarrhea, incoordination and neck tremble, minority chronic diseaseThere is the symptoms such as neck is crooked in example. In pathology with fibrinous pericarditis, perihepatitis, air bag inflammation, brainFilm inflammation and some cases occur that arthritis is feature, often cause large quantities of morbidities and the death of duckling, the results are shown inTable 7.
The therapeutic test of table 7 Riemerella anatipestifer disease
Result shows: the cure rate of high, the middle dosage group of test group and control group is more than 90%, showsThe effect of dry suspensoid agent treatment Riemerella anatipestifer disease of the present invention is remarkable.
To sum up, pharmaceutical composition of the present invention is prepared under specific consumption by specific supplementary material, Neng GouyouEffect treatment chicken/E. coli isolated from ducks disease, white diarrhea and Riemerella anatipestifer disease, cure rate all reaches 92%.Pharmaceutical composition of the present invention is suitable for poultry to be swallowed, efficient, inexpensive, safety, steady quality, technique is simple,Easy to use, be convenient to storage and transport, for clinical treatment poultry bacterial disease provides a kind of new medicineThing, has wide market prospects.
Claims (7)
1. a pharmaceutical composition for the treatment of poultry bacterial disease, is characterized in that: it is by following heavyThe dry suspensoid agent that the supplementary material of amount proportioning is prepared from:
Herba portulacae 6.67-80.04 part, barberry 3.33-39.96 part, sorbierite 8-16 part, poloxamer0-4 part.
2. pharmaceutical composition according to claim 1, is characterized in that: it is to be joined by following weightThe dry suspensoid agent that the supplementary material of ratio is prepared from:
Herba portulacae 66.67g part, 33.33 parts of barberries, 16 parts of sorbierites, 2 parts of poloxamers.
3. the method for the pharmaceutical composition of preparation described in claim 1 or 2, is characterized in that: comprise asLower step:
A, the Herba portulacae of getting recipe quantity, barberry are pulverized respectively, mix, then carry out ultramicro grinding, obtain superMicro mist;
B, the Ultramicro-powder of getting step a add sorbierite, poloxamer, decoct, and dry, and pulverize, sieve,Obtain.
4. method according to claim 3, is characterized in that:
In step a, Herba portulacae, barberry are pulverized respectively as fine powder, crossed 65 mesh sieves, then use " V "Type mixer mixes 1 hour; In step b, decoct 15-60 minute, dry to moisture 10% withUnder, cross 100-400 mesh sieve.
5. method according to claim 4, is characterized in that:
In step b, decoct 15 minutes, cross 400 mesh sieves.
6. the pharmaceutical composition described in claim 1 or 2 is at the medicine of preparation treatment poultry bacterial diseaseIn purposes.
7. purposes according to claim 6, is characterized in that: described medicine is that treatment chicken/duck is largeThe medicine of enterobacteria disease, white diarrhea and Riemerella anatipestifer disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610054946.5A CN105582037A (en) | 2016-01-27 | 2016-01-27 | Medicine composition for treating bacterial diseases of poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610054946.5A CN105582037A (en) | 2016-01-27 | 2016-01-27 | Medicine composition for treating bacterial diseases of poultry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105582037A true CN105582037A (en) | 2016-05-18 |
Family
ID=55922193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610054946.5A Withdrawn CN105582037A (en) | 2016-01-27 | 2016-01-27 | Medicine composition for treating bacterial diseases of poultry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105582037A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102846614A (en) * | 2011-06-29 | 2013-01-02 | 王洪涛 | Veterinary drug for treating bacterial disease of fowl |
| CN103127198A (en) * | 2013-03-01 | 2013-06-05 | 成都乾坤动物药业有限公司 | Combined drug for treating piglet's yellow-white dysentery |
| CN104161207A (en) * | 2013-07-18 | 2014-11-26 | 河南联合英伟饲料有限公司 | Feed additive for resisting duck bacterial diseases, preparation method and application |
| CN105395835A (en) * | 2015-12-23 | 2016-03-16 | 青岛汉河动植物药业有限公司 | Traditional Chinese medicine composition used for treating escherichia coli infection in brooding stage of poultry |
-
2016
- 2016-01-27 CN CN201610054946.5A patent/CN105582037A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102846614A (en) * | 2011-06-29 | 2013-01-02 | 王洪涛 | Veterinary drug for treating bacterial disease of fowl |
| CN103127198A (en) * | 2013-03-01 | 2013-06-05 | 成都乾坤动物药业有限公司 | Combined drug for treating piglet's yellow-white dysentery |
| CN104161207A (en) * | 2013-07-18 | 2014-11-26 | 河南联合英伟饲料有限公司 | Feed additive for resisting duck bacterial diseases, preparation method and application |
| CN105395835A (en) * | 2015-12-23 | 2016-03-16 | 青岛汉河动植物药业有限公司 | Traditional Chinese medicine composition used for treating escherichia coli infection in brooding stage of poultry |
Non-Patent Citations (1)
| Title |
|---|
| 胡郁坤 等: "《袖珍中药应用速查手册》", 31 July 2012, 湖南科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101584747B (en) | Antibacterial antivirus Chinese medicinal composition for animal | |
| CN100462089C (en) | Yukangsan herb medicine powder for treating fish diseases | |
| CN102670516A (en) | Tilmicosin soluble powder and preparation method thereof | |
| CN106667915B (en) | It is a kind of for treating the scutelloside aluminium dry suspensoid agent of grice diarrhoea | |
| CN104686866A (en) | Decavitamin and fermented Chinese traditional medicinal herb preparation special for postpartum breeding sows and preparing method and application thereof | |
| CN102258635B (en) | Antibacterial Chinese medicine for veterinary use | |
| CN103623121B (en) | A kind of for thousand order Chinese veterinary drug preparation of preventing and treating livestock and birds respiratory disease and preparation method thereof | |
| CN104069266B (en) | A kind of plant essential oil composition for animals | |
| CN101085037B (en) | Traditional Chinese medicine preparation for animals and preparation method thereof | |
| CN105582037A (en) | Medicine composition for treating bacterial diseases of poultry | |
| CN102218078B (en) | Rifaximin suspension containing montmorillonite and preparation method thereof | |
| CN110403093B (en) | Laying hen feed additive | |
| CN107233475A (en) | A kind of Chinese medicine composition, its preparation method and application for preventing and treating birds alimentary canal bacteriosis | |
| CN112716987A (en) | Premixed preparation for preventing and treating intestinal inflammation disease of lasalopecuroide and preparation method thereof | |
| CN103520267A (en) | Wettable experimental pullorum evapotranspiration and preparation method thereof | |
| CN105746846B (en) | South dodder seed and motherwort herb pharmaceutical composition, and premix, concentrate, batch and application thereof | |
| CN104758347B (en) | Traditional Chinese medicine oral liquid for treating pullorum disease and preparation method thereof | |
| CN107029162A (en) | Pharmaceutical composition, preparation method and the preparation of enhancing development | |
| CN102319318B (en) | Chinese medicinal superfine powder preparation for preventing and treating heat toxin and blood dysentery of chicken and preparation method thereof | |
| CN104770618B (en) | A kind of Chinese herbal feed additive and preparation method thereof, purposes | |
| CN105878875A (en) | Traditional Chinese medicine ultra-micro powder granules for preventing and treating necrotic enteritis of poultry and preparation method thereof | |
| CN114425069B (en) | Special forage grass formula for preventing male forest musk lithiasis | |
| CN113940966B (en) | Callicarpa nudiflora composition for treating escherichia coli infection and preparation method and application thereof | |
| CN104188919B (en) | A kind of livestock and poultry Thiamphenicol dried bean noodles supensoid agent and preparation method thereof | |
| CN103053826A (en) | Growth-promoting Chinese herbal medicine feed additive for chickens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160518 |